Sector: Consumer Non-Cyclicals | Industry: Personal Products |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 300 PARK AVE NEW YORK NY 10022-7402 |
Tel: | N/A |
Website: | https://www.colgatepalmolive.com |
IR: | See website |
Key People | ||
Noel R. Wallace Chairman of the Board, President, Chief Executive Officer | Stanley J. Sutula Chief Financial Officer | Prabha Parameswaran Group President - Growth and Strategy |
Panagiotis Tsourapas Group President, Europe and Developing Markets | Sally Massey Chief Human Resource Officer | Gregory Malcolm Executive Vice President, Controller |
John W. Kooyman Chief of Staff | Jennifer M. Daniels Chief Legal Officer and Secretary |
Business Overview |
Colgate-Palmolive Company manufactures a range of products for the personal and home care markets. It operates in two product segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care product segment is managed geographically in five segments, such as North America, Latin America, Europe, Asia Pacific and Africa/Eurasia, all of which sell primarily to a variety of traditional and e-commerce retailers, wholesalers, distributors, dentists and skin health professionals. The Company sells its products under brands, such as Colgate, Palmolive, elmex, hello, meridol, Sorriso, Tom's of Maine, EltaMD, Filorga, Irish Spring, PCA SKIN, Protex, Sanex, Softsoap, Speed Stick, Ajax, Axion, Fabuloso, Soupline and Suavitel, as well as Hill's Science Diet and Hill's Prescription Diet. Through Hill's Pet Nutrition, it is also engaged in the pet nutrition market, selling products principally through authorized pet supply retailers, veterinarians and e-commerce retailers. |
Financial Overview |
For the three months ended 31 March 2024, Colgate-Palmolive Company revenues increased 6% to $5.07B. Net income increased 84% to $683M. Revenues reflect Oral, Personal and Home Care segment increase of 7% to $3.96B, Pet Nutrition segment increase of 4% to $1.1B, Latin America segment increase of 17% to $1.25B, Europe segment increase of 9% to $711M, North America segment increase of 4% to $997M. Net income benefited from Oral. |
Employees: | 34,000 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $83,582M as of Mar 31, 2024 |
Annual revenue (TTM): | $19,752M as of Mar 31, 2024 |
EBITDA (TTM): | $4,769M as of Mar 31, 2024 |
Net annual income (TTM): | $2,611M as of Mar 31, 2024 |
Free cash flow (TTM): | $1,270M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | $7,379M as of Mar 31, 2024 |
Shares outstanding: | 820,441,114 as of Mar 31, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |